semaglutide 0.2 ml FDA approves once-a-week diabetes shot that also aids weight loss FDA warns about compounded versions

Trial ESSENCE (Sanyal et al., NEJM 2025) Design Phase 3 / 72 weeks (Part 1) Population Adults with MASH, F2-F3 fibrosis Key result 33% achieved both steatohepatitis resolution and fibrosis improvement vs 16% placebo

Persistent or worsening symptoms warrant further evaluation

GLP-1 app addresses this by centralizing injection schedules, protein targets, hydration tracking, and side-effect monitoring in a single interface that reveals patterns most people miss when relying on memory alone

The cornerstone of management is maintaining adequate hydration

Tirzepatide Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist